Drugs Made In America Acquisition Corp. (DMAAR) Cash & Equivalents (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Cash & Equivalents for 3 consecutive years, with $20280.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 2367.15% year-over-year to $20280.0; the trailing twelve-month figure through Jun 2026 stood at $20280.0 (up 2367.15% YoY), and the FY2025 full-year result was $6137.0, up 354.26% from the prior year.
• Cash & Equivalents advanced to $20280.0 in Q2 2026 per DMAAR's latest filing, from $6137.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $20280.0 in Q2 2026 and bottomed at $717.0 in Q3 2025.
• Historically, Cash & Equivalents has averaged $5038.3 across 3 years, with a median of $1137.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 354.26% in 2025, then jumped 2367.15% in 2026.
• Over 3 years, Cash & Equivalents stood at $1351.0 in 2024, then jumped by 354.26% to $6137.0 in 2025, then jumped by 230.45% to $20280.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $20280.0, $6137.0, and $717.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.